Follow along as we discuss the latest changes across the pharmaceutical, biotechnology, medical technology and life science sectors.

  • External Factors Impacting Medical Device Post-Approval Compliance

    External Factors Impacting Medical Device Post-Approval Compliance

    The Impact of the 3G Network Shutdown on Medical Device Post-Approval Compliance in Australia. After over two decades of service, 3G networks in Australia were officially decommissioned on October 28, 2024, to make way for faster and more reliable 4G and 5G technologies. In addition to the impact on 3G-only phones, remote areas, and smartwatches,…

  • 2024 A Year in Review

    2024 A Year in Review

    As we approach the close of 2024, it’s essential to reflect on our achievements, growth, and the incredible progress we’ve made together. This year has been transformative, marked by milestones that position the Adjutor Healthcare Group for even greater success in 2025. As we look forward, we remain committed to innovation, collaboration, and delivering exceptional…

  • Advertising and Promotional Material Review for Therapeutic Goods in Australia

    Advertising and Promotional Material Review for Therapeutic Goods in Australia

    Navigating advertising compliance for therapeutic goods in Australia can feel like walking a tightrope. With multiple advertising laws enforced by different regulators, businesses must tread carefully to avoid penalties or legal complications.

Stay up to date with the latest news and industry developments in Australia/New Zealand and beyond.

Breaking news and updates about the regulation of therapeutic goods in Australia.

  • MEDSAFE NZ Moves Ahead in 2020

    MEDSAFE NZ Moves Ahead in 2020

    Since 2015, Medsafe NZ, the New Zealand Medicines and Medical Devices Safety Authority, has been working on a new therapeutic products regulatory regime to replace and modernise the regulatory arrangements for medicines, and provide regulation of all therapeutic products. Whilst we are still waiting for the progression of the Therapeutic Products Bill through parliament, the

  • Consumer Insecurity / Vanity Targeted by TGA – Massive Fines

    Consumer Insecurity / Vanity Targeted by TGA – Massive Fines

    The appearance of misleading terms and claims on websites and social media has attracted the attention of the TGA. The Therapeutic Goods Administration in Australia (TGA) has advised that fines were imposed via the Federal Court for misleading advertising by Peptide Clinics Australia (Peptide Clinics Pty Ltd), to the tune of $10 million (for breaches…

Contact us today and let’s work together to achieve your goals. Whether you have a question, need more information, or want to discuss your project, our team is here to help.